Voyager Therapeutics, Inc.

Stage 4 · Declining · week 22

As of Oct 22, 2026, Voyager Therapeutics is in Stage 4, the downtrend phase, now in week 22 (since May 21, 2026). It closed at $1.86, 62.8% below its 52-week high and below its 200-day average, which is falling.

Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. More about the company

$1.86

-7.92% today

$115M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is VYGR early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S1 14w

S4 37w

S3 14w

S4 22w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S3 6w → S4 12w → S1 14w → S2 7w → S3 8w → S2 3w → S3 1w → S4 12w → S1 3w → S4 37w → S1 8w → S2 9w → S3 14w → S1 3w → S4 1w → S1 4w → S4 22w current

Total tracked: 165 weeks across 17 stage runs.

VYGR among Biotechnology398th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…398	VYGRVoyager Therapeutics, Inc.	Stage 4 · wk 22	18	−35.2%

vs 52W High

-62.8%

$1.86 lo$5.00 hi

62.8% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 22

1w13w26w

Week 22, extended decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-47.3%

200 DMA: $3.53 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

2.10x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-35.2%

-40.0%

-54.0%

YTD

-53.8%

-62.6%

Scan Membership

Breakout Watch

Latest: 2024-07-22

8 appearances in last 60 days. First seen: 2019-04-09.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 22 · Vol 2.10x

2026-10-21S4

Wk 22 · Vol 1.37x

2026-10-20S4

Wk 21 · Vol 1.89x

2026-10-19S4

Wk 21 · Vol 2.17x

2026-10-16S4

Wk 21 · Vol 0.99x

2026-10-15S4

Wk 21 · Vol 1.25x

2026-10-14S4

Wk 21 · Vol 2.13x

2026-10-13S4

Wk 20 · Vol 1.93x

2026-10-12S4

Wk 20 · Vol 1.79x

2026-10-09S4

Wk 20 · Vol 1.30x

2026-10-08S4

Wk 20 · Vol 1.77x

2026-10-07S4

Wk 20 · Vol 1.47x

Moving averages & range

50 DMA

$2.90

200 DMA

$3.53

52W High

$5.00

52W Low

$1.86

5D Low

$1.86

Resistance levels (recent highs)

20d High

$2.70

60d High

$3.54

120d High

$4.24

250d High

$5.00

Next resistance

+45.2%

to 20d High

ROE

-54.1%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 0.7

Voyager Therapeutics: quick answers

What stage is Voyager Therapeutics in?

As of Oct 22, 2026, Voyager Therapeutics (VYGR) is in Stage 4, the downtrend phase. It entered Stage 4 on May 21, 2026 and is in week 22. What the four stages mean

Is Voyager Therapeutics in an uptrend?

No. Voyager Therapeutics is in a Stage 4 downtrend. It trades 47.3% below its 200-day average, which is falling.

How far is Voyager Therapeutics from its 52-week high?

Voyager Therapeutics closed at $1.86 on Oct 22, 2026, 62.8% below its 52-week high of $5.00. Its 52-week low is $1.86.

How has Voyager Therapeutics performed over the past year?

As of Oct 22, 2026, Voyager Therapeutics is down 62.6% over the past year and down 53.8% so far in 2026.

Which sector and industry is Voyager Therapeutics in?

Voyager Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease. The company also provides research program for the treatment of Huntington's disease. In addition, it offers TRACER, an adeno-associated virus (AAV) capsid discovery platform; ALPL-VYGR-NeuroShuttle, to target an undisclosed neurological disease; and develops selective small molecules for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia with TDP-43 pathology. The company has collaboration and license agreements with Alexion; AstraZeneca Ireland Limited; Novartis Pharma AG; and Transition Bio, Inc. for the treatment of various other diseases of the central nervous system. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.